Sutro Biopharma Current Ratio 2017-2022 | STRO

Sutro Biopharma current ratio from 2017 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Sutro Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.35B $0.06B 5.95
2022-06-30 $0.33B $0.05B 7.44
2022-03-31 $0.23B $0.04B 5.90
2021-12-31 $0.22B $0.04B 5.24
2021-09-30 $0.25B $0.04B 7.07
2021-06-30 $0.28B $0.03B 10.63
2021-03-31 $0.27B $0.02B 11.74
2020-12-31 $0.38B $0.03B 12.78
2020-09-30 $0.29B $0.03B 9.77
2020-06-30 $0.26B $0.04B 7.29
2020-03-31 $0.13B $0.03B 3.98
2019-12-31 $0.13B $0.03B 3.90
2019-09-30 $0.14B $0.04B 3.78
2019-06-30 $0.16B $0.04B 4.49
2019-03-31 $0.18B $0.03B 5.67
2018-12-31 $0.21B $0.04B 5.76
2018-09-30 $0.13B $0.04B 3.45
2018-06-30 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $0.00B 0.00
2017-09-30 $0.00B 0.00
2016-12-31 $0.05B $0.05B 0.99
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.409B $0.062B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00